MP46-12 DECLINES IN SKELETAL MUSCLE MASS AND QUALITY DURING CYTOTOXIC CHEMOTHERAPY PREDICT INCREASED RISK OF CHEMOTHERAPY-ASSOCIATED ADVERSE EVENTS IN MEN WITH TESTIS CANCER. (May 2022)